Sanofi acquires US vaccines biotech for $650M: 3 things to know

Paris-based Sanofi will buy Protein Sciences, a Meriden, Conn.-based vaccines biotech, for a $650 million upfront payment, reports Reuters.

Here are three things to know.

  1. Protein Sciences is also eligible to receive up to $100 million in milestone payments.

  1. Through the acquisition, Sanofi will gain the rights to the flu vaccine Flublok. Unlike most vaccines grown in chicken eggs, Flublok is produced using a technology that rearranges genetic material to make the vaccine.

  2. The deal is expected to close in the third quarter of this year.

More articles on supply chain:

How Trump's efforts to lower drug prices affect the industry — 4 questions on a possible executive order
Suburban Hospital wants to compete with MedStar Georgetown for liver transplants
Why supply chain leaders should practice unlearning

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like

 

Featured Whitepapers

Featured Webinars